Personal tools
Dr. Rebecca Gladdy
You are here: Home → Researchers → Dr. Rebecca Gladdy

 

gladdy  

Dr. Rebecca Gladdy

ASSOCIATE MEMBER


Soft tissue sarcomas (STS) are a diverse group of tumors derived from connective tissue (muscle, fat and bone). Current treatment of STS is limited primarily to surgical procedures (e.g., removing the sarcoma), with selective use of radiation therapy and the use of conventional chemotherapy in some subtypes of the disease. Unfortunately, these treatment options are limited in their effectiveness and more than 50 per cent of STS patients succumb to this disease. Researchers have recognized that there is an urgent need to develop subtype-specific molecularly targeted therapeutics that can provide new treatment options unique to each histologic type of sarcoma.
 
Samuel Lunenfeld Research Institute
600 University Avenue
Room 1070B
Toronto Ontario M5G 1X5
t 416-586-4800 x 3896
Send Email

 
Jul 29, 2009 01:20 PM

     

At a Glance

  • Appointed to the department of surgery at Mount Sinai Hospital

  • Surgical Oncology specializing in sarcoma

  • Received an Ontario Institute for Cancer Research Clinician Scientist Award

 

 

Major Research Activities

The main goals of the Selective Therapies program are:

  • to identify targeted therapeutic agents through the use of high-throughput screens in collaboration with the Ontario Node of the Terry Fox Research Institute and the SMART facility at the Samuel Lunenfeld Research Institute;
  • to develop faithful and genetically flexible mouse models of sarcoma as a tool to functionally validate genomic data and for pre-clinical drug testing;
  • to readily translate laboratory findings via clinical trials to sarcoma patients in Ontario.

 

 

Selected Publications


Matei IR, Gladdy RA, Nutter LMJ, Guidos CJ and JS Danska. ATM deficiency disrupts TCRalocus integrity and the maturation of CD4+CD8+thymocytes. Blood. 2007;109(5):1887-1996.

Khalifa MA, Rowsell CH, Gladdy RA, Ko JY, Hanna S, Smith AJ, and Law C . Is EGFR expression altered following postoperative chemotherapy for colorectal adenocarcinoma? World Journal of Surgical Oncology. 2006;Dec 12;4:92.
Gladdy RA, Nutter LMJ, Kunath T, Danska JS and CJ Guidos. p53-Independent Apoptosis Disrupts Early Organogenesis in Embryos Lacking Both ATM and Prkdc.  Mol Cancer Res. 2006;4(5):311-8.

Khalifa MA, Rowsell CH, Gladdy RA, Ko JY, Hanna S, Smith AJ, and C Law. Immunohistochemical Assessment of Epidermal Growth Factor Receptor in Primary Colorectal Adenocarcinoma as a Predictor of Recurrence. 2006;125:1-5. American Journal of Clinical Pathology.

 

Gladdy RA, Taylor MD, Williams CJ, Rutka JT, Karaskova J, Squire J, Guidos CJ and Danska JS. The RAG-1/2 endonuclease causes genomic instability and controls CNS complication of lymphoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell. 2003;3:37-50.

 

 

Document Actions
 
[RSS]